<DOC>
	<DOCNO>NCT01292135</DOCNO>
	<brief_summary>The purpose study establish safety orally administer PCI-32765 combination fludarabine/cyclophosphamide/rituximab ( FCR ) bendamustine/rituximab ( BR ) patient chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) .</brief_summary>
	<brief_title>Safety Tolerability Study PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab ( FCR ) Bendamustine/Rituximab ( BR ) Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>This Phase 1b , open-label , parallel-group , nonrandomized , multicenter study PCI 32765 420 mg daily oral ( PO ) administration combination 2 different chemotherapy regimens subject relapsed/refractory chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Histologically confirm CLL SLL satisfy least 1 follow criterion require treatment : Progressive splenomegaly and/or lymphadenopathy identify physical examination radiographic study Anemia ( &lt; 11 g/dL ) thrombocytopenia ( &lt; 100,000/μL ) due bone marrow involvement Presence unintentional weight loss &gt; 10 % precede 6 month NCI CTCAE Grade 2 3 fatigue Fevers &gt; 100.5° night sweat &gt; 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2 month period anticipate doubling time &lt; 6 month 2 . 1 3 prior treatment regimen CLL/SLL 3 . ECOG performance status ≤ 1 4 . ≥ 18 year age 5 . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty 6 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) 1 . Any chemotherapy , therapeutic antineoplastic antibody ( include radio toxin immunoconjugates ) , radiation therapy , experimental antineoplastic therapy within 4 week first dose study drug 2 . Radio toxinconjugated antibody therapy within 10 week first dose study drug 3 . Concomitant use medicine know cause QT prolongation torsades de point 4 . Transformed lymphoma Richter 's transformation Any lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism PCI32765 PO , put study outcome undue risk 5 . Any following laboratory abnormality : oAbsolute neutrophil count ( ANC ) &lt; 1000 cells/mm3 ( 1.0 x 109/L ) oPlatelet count &lt; 50,000/mm3 ( 50 x 109/L ) oSerum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ≥ 3.0 x upper limit normal ( ULN ) oCreatinine &gt; 2.0 x ULN creatinine clearance &lt; 40 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Leukemia , Lymphoid</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
</DOC>